Now in its third edition, the book builds on Exclaimer’s two decades of expertise helping enterprises transform everyday emails into consistent, compliant, and high-performing communications. It ...

China's EV giant unveils a $283 million mega-facility as regulators worldwide zero in on electric vehicle safety risks.

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Vikki Velasquez is a researcher and ...

The drama involving FanFan and The Streamer Awards 2025 continues to go on. It started from a joke delivered onstage by Fiona "Fanfan" during an audience segment. It eventually sparked backlash and ...

Want more stock market and economic analysis from Phil Rosen directly in your inbox? Subscribe to Opening Bell Daily’s newsletter. Stocks typically do well in December but the current setup favors the ...

Dividend-paying stocks that combine healthy balance sheets with hefty yields can provide investors with steady incomes, cushion against market downturns, and grow investments at a healthy clip. Over ...

Here’s a look at three high-quality dividend-payers, plus two monthly and two high-yield options that may suit your investing needs in 2026. If the recent run-up in growth stocks has made your ...

The November 2025 high-yield dividend watchlist delivered a 2.94% gain in last month, outperforming SPY and closely trailing VYM. This watchlist blends quality and value to identify high-yield stocks ...

In a rocky market, dividend stocks can offer a measure of stability. Companies that consistently grow dividends and throw off healthy amounts of cash should deliver solid returns in 2026.

Plus, several undervalued stocks to buy with stable dividends. They name-drop a few undervalued stocks that Morningstar thinks have stable dividends, cover why dividend growth stock investing is ...

Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for ...